HK1159129A1 - Novel immunogenic epitopes for immunotherapy - Google Patents
Novel immunogenic epitopes for immunotherapyInfo
- Publication number
- HK1159129A1 HK1159129A1 HK11113659.2A HK11113659A HK1159129A1 HK 1159129 A1 HK1159129 A1 HK 1159129A1 HK 11113659 A HK11113659 A HK 11113659A HK 1159129 A1 HK1159129 A1 HK 1159129A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- immunotherapy
- immunogenic epitopes
- novel immunogenic
- novel
- epitopes
- Prior art date
Links
- 230000002163 immunogen Effects 0.000 title 1
- 238000009169 immunotherapy Methods 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/495—Transforming growth factor [TGF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
- C12N9/0036—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on NADH or NADPH (1.6)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/13—Transferases (2.) transferring sulfur containing groups (2.8)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
- C12N2502/1157—Monocytes, macrophages
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y208/00—Transferases transferring sulfur-containing groups (2.8)
- C12Y208/02—Sulfotransferases (2.8.2)
- C12Y208/02011—Galactosylceramide sulfotransferase (2.8.2.11)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07014797 | 2007-07-27 | ||
US95316107P | 2007-07-31 | 2007-07-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1159129A1 true HK1159129A1 (en) | 2012-07-27 |
Family
ID=39766525
Family Applications (7)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK11113659.2A HK1159129A1 (en) | 2007-07-27 | 2011-12-19 | Novel immunogenic epitopes for immunotherapy |
HK13109940.7A HK1183039A1 (en) | 2007-07-27 | 2013-08-26 | Novel immunogenic epitopes for immunotherapy |
HK13109945.2A HK1183041A1 (en) | 2007-07-27 | 2013-08-26 | Novel immunogenic epitopes for immunotherapy |
HK13109939.0A HK1183038A1 (en) | 2007-07-27 | 2013-08-26 | Novel immunogenic epitopes for immunotherapy |
HK13109944.3A HK1183040A1 (en) | 2007-07-27 | 2013-08-26 | Novel immunogenic epitopes for immunotherapy |
HK16111627.0A HK1223381A1 (zh) | 2007-07-27 | 2016-10-06 | 免疫療法的新型免疫抗原表位 |
HK16111656.4A HK1223382A1 (zh) | 2007-07-27 | 2016-10-07 | 免疫療法的新型免疫抗原表位 |
Family Applications After (6)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK13109940.7A HK1183039A1 (en) | 2007-07-27 | 2013-08-26 | Novel immunogenic epitopes for immunotherapy |
HK13109945.2A HK1183041A1 (en) | 2007-07-27 | 2013-08-26 | Novel immunogenic epitopes for immunotherapy |
HK13109939.0A HK1183038A1 (en) | 2007-07-27 | 2013-08-26 | Novel immunogenic epitopes for immunotherapy |
HK13109944.3A HK1183040A1 (en) | 2007-07-27 | 2013-08-26 | Novel immunogenic epitopes for immunotherapy |
HK16111627.0A HK1223381A1 (zh) | 2007-07-27 | 2016-10-06 | 免疫療法的新型免疫抗原表位 |
HK16111656.4A HK1223382A1 (zh) | 2007-07-27 | 2016-10-07 | 免疫療法的新型免疫抗原表位 |
Country Status (17)
Country | Link |
---|---|
US (5) | US8080634B2 (es) |
EP (7) | EP2562184B1 (es) |
JP (4) | JP5484326B2 (es) |
KR (3) | KR101313915B1 (es) |
CN (3) | CN101765610B (es) |
AU (1) | AU2008281014B2 (es) |
BR (1) | BRPI0813626A2 (es) |
CA (1) | CA2694805C (es) |
EA (1) | EA018456B1 (es) |
ES (7) | ES2555282T3 (es) |
HK (7) | HK1159129A1 (es) |
HU (5) | HUE027057T2 (es) |
MX (1) | MX2010001090A (es) |
NZ (1) | NZ582822A (es) |
PL (7) | PL3042914T3 (es) |
UA (2) | UA103751C2 (es) |
WO (1) | WO2009015842A2 (es) |
Families Citing this family (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK1716234T3 (da) * | 2004-02-20 | 2014-01-20 | Mologen Ag | Substitueret, ikke-kodende nukleinsyremolekyle til terapeutisk og profylaktisk immunstimulering i mennesker og højerestående dyr |
US9732131B2 (en) | 2006-02-27 | 2017-08-15 | Calviri, Inc. | Identification and use of novopeptides for the treatment of cancer |
US20090004213A1 (en) * | 2007-03-26 | 2009-01-01 | Immatics Biotechnologies Gmbh | Combination therapy using active immunotherapy |
GB201004575D0 (en) * | 2010-03-19 | 2010-05-05 | Immatics Biotechnologies Gmbh | Composition of tumor associated peptides and related anti cancer vaccine for the treatment of gastric cancer and other cancers |
GB201004551D0 (en) | 2010-03-19 | 2010-05-05 | Immatics Biotechnologies Gmbh | NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer |
GB201019331D0 (en) * | 2010-03-19 | 2010-12-29 | Immatics Biotechnologies Gmbh | Methods for the diagnosis and treatment of cancer based on AVL9 |
CN102183640A (zh) * | 2011-01-31 | 2011-09-14 | 浙江大学 | 筛选和鉴定乙肝病毒特异性细胞毒性t淋巴细胞表位方法 |
CN102168066A (zh) * | 2011-01-31 | 2011-08-31 | 浙江大学 | 体外诱导乙型肝炎病毒特异性细胞毒性t淋巴细胞的方法 |
WO2013054320A1 (en) * | 2011-10-11 | 2013-04-18 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam) |
US20130302366A1 (en) * | 2012-05-09 | 2013-11-14 | Christopher Marshall | Conformationally Specific Viral Immunogens |
PT3456339T (pt) * | 2013-08-05 | 2021-12-09 | Immatics Biotechnologies Gmbh | Nova imunoterapia contra vários tumores, tais como cancro do pulmão, incluindo cpnpc |
GB201319446D0 (en) | 2013-11-04 | 2013-12-18 | Immatics Biotechnologies Gmbh | Personalized immunotherapy against several neuronal and brain tumors |
MX2019013161A (es) * | 2013-11-04 | 2020-02-03 | Immatics Biotechnologies Gmbh | Inmunoterapia personalizada contra diversos tumores cerebrales y neuronales. |
US10293035B2 (en) | 2014-03-28 | 2019-05-21 | University Of Washington Through Its Center For Commercialization | Breast and ovarian cancer vaccines |
MX366359B (es) | 2014-04-27 | 2019-07-05 | Ccam Biotherapeutics Ltd | Anticuerpos humanizados contra la molecula de adhesion celular relacionada al antigeno carcinoembrionico 1 (ceacam1). |
US11427647B2 (en) | 2014-04-27 | 2022-08-30 | Famewave Ltd. | Polynucleotides encoding humanized antibodies against CEACAM1 |
IL248203A0 (en) | 2014-05-09 | 2016-11-30 | Immatics Biotechnologies Gmbh | Innovative immunotherapy against blood tumors such as acute leukemia in the spinal cord |
GB201408255D0 (en) * | 2014-05-09 | 2014-06-25 | Immatics Biotechnologies Gmbh | Novel immunotherapy against several tumours of the blood, such as acute myeloid leukemia (AML) |
GB201504502D0 (en) * | 2015-03-17 | 2015-04-29 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers |
TWI755157B (zh) | 2015-03-17 | 2022-02-11 | 德商英麥提克生物技術股份有限公司 | 用於抗胰臟癌與其他癌症的免疫治療的新穎胜肽及胜肽的組合 |
GB201505305D0 (en) | 2015-03-27 | 2015-05-13 | Immatics Biotechnologies Gmbh | Novel Peptides and combination of peptides for use in immunotherapy against various tumors |
KR20220167337A (ko) | 2015-03-27 | 2022-12-20 | 이매틱스 바이오테크놀로지스 게엠베하 | 다양한 종양에 대한 면역요법에서의 사용을 위한 펩티드 및 펩티드의 조합 |
GB201505585D0 (en) * | 2015-03-31 | 2015-05-13 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carinoma (RCC) and other cancers |
GB201507030D0 (en) | 2015-04-24 | 2015-06-10 | Immatics Biotechnologies Gmbh | Immunotherapy against lung cancers, in particular NSCLC |
GB201507719D0 (en) * | 2015-05-06 | 2015-06-17 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers |
CR20230131A (es) * | 2015-05-06 | 2023-06-23 | Immatics Biotechnologies Gmbh | NUEVOS PÉPTIDOS Y NUEVAS COMBINACIONES DE PÉPTIDOS Y DE SOPORTES PARA LA INMUNOTERAPIA CONTRA EL CARCINOMA COLORRECTAL Y OTROS TIPOS DE CÁNCER (Divisional Exp. 2017-0497) |
NL2014935B1 (en) | 2015-06-08 | 2017-02-03 | Applied Immune Tech Ltd | T cell receptor like antibodies having fine specificity. |
CR20200525A (es) * | 2015-06-19 | 2020-12-23 | Immatics Biotechnologies Gmbh | NUEVOS PÉPTIDOS Y NUEVAS COMBINACIONES DE PÉPTIDOS PARA EL USO EN LA INMUNOTERAPIA Y MÉTODOS PARA CREAR SOPORTES PARA EL USO CONTRA EL CÁNCER DE PÁNCREAS Y OTROS TIPOS DE CÁNCER (Divisional 2018-0040) |
GB201510771D0 (en) | 2015-06-19 | 2015-08-05 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy and methods for generating scaffolds for the use against pancreatic cancer |
GB201511191D0 (en) * | 2015-06-25 | 2015-08-12 | Immatics Biotechnologies Gmbh | T-cell epitopes for the immunotherapy of myeloma |
GB201511546D0 (en) * | 2015-07-01 | 2015-08-12 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers |
EP3919507A3 (en) | 2015-07-01 | 2022-01-12 | Immatics Biotechnologies GmbH | Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers |
GB201512369D0 (en) * | 2015-07-15 | 2015-08-19 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers |
GB201515321D0 (en) | 2015-08-28 | 2015-10-14 | Immatics Biotechnologies Gmbh | Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers |
US10130693B2 (en) | 2015-08-28 | 2018-11-20 | Immatics Biotechnologies Gmbh | Peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers |
CA3223546A1 (en) | 2015-08-28 | 2017-03-09 | Immatics Biotechnologies Gmbh | Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers |
LU92821B1 (en) | 2015-09-09 | 2017-03-20 | Mologen Ag | Combination comprising immunostimulatory oligonucleotides |
GB2542425A (en) | 2015-09-21 | 2017-03-22 | Mologen Ag | Means for the treatment of HIV |
GB201521894D0 (en) * | 2015-12-11 | 2016-01-27 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against various cancers |
IL259931B2 (en) | 2015-12-16 | 2024-02-01 | Gritstone Bio Inc | Identification of neo-antigens, preparation, and use |
GB201603987D0 (en) * | 2016-03-08 | 2016-04-20 | Immatics Biotechnologies Gmbh | Uterine cancer treatments |
GB201604458D0 (en) * | 2016-03-16 | 2016-04-27 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against cancers |
JP7075125B2 (ja) | 2016-05-25 | 2022-05-25 | イマティクス バイオテクノロジーズ ゲーエムベーハー | 標的としてのおよび胆嚢がんおよび胆管がんおよびその他のがんに対する免疫療法で使用するための新規ペプチド、ペプチド組み合わせ |
GB201609193D0 (en) | 2016-05-25 | 2016-07-06 | Immatics Biotechnologies Gmbh | Novel peptides, combination of peptides as targets for use in immunotherapy against gallbladder cancer and cholangiocarcinoma and other cancers |
TW202304970A (zh) * | 2016-08-26 | 2023-02-01 | 德商英麥提克生物技術股份有限公司 | 用於頭頸鱗狀細胞癌和其他癌症免疫治療的新型肽和支架 |
DE102016123893A1 (de) | 2016-12-08 | 2018-06-14 | Immatics Biotechnologies Gmbh | T-Zellrezeptoren mit verbesserter Bindung |
EP4317432A3 (en) | 2016-12-08 | 2024-04-17 | Immatics Biotechnologies GmbH | T cell receptors with improved pairing |
AR110857A1 (es) | 2017-01-27 | 2019-05-08 | Immatics Biotechnologies Gmbh | Péptidos y combinaciones de péptidos para el uso en la inmunoterapia contra el cáncer de ovario y otros tipos de cáncer |
MA47367B1 (fr) * | 2017-01-27 | 2023-06-28 | Immatics Biotechnologies Gmbh | Nouveaux peptides et combinaison de peptides à utiliser en immunothérapie contre le cancer de l'ovaire et d'autres cancers |
EP3573647B1 (en) | 2017-01-27 | 2023-04-05 | Immatics Biotechnologies GmbH | Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers |
WO2018223094A1 (en) | 2017-06-02 | 2018-12-06 | Arizona Board Of Regents On Behalf Of Arizona State University | A method to create personalized canine cancer vaccines |
US20200209241A1 (en) | 2017-09-15 | 2020-07-02 | Arizona Board Of Regents On Behalf Of Arizona State University | Methods of classifying response to immunotherapy for cancer |
AU2018348165A1 (en) | 2017-10-10 | 2020-05-21 | Gritstone Bio, Inc. | Neoantigen identification using hotspots |
KR20200090855A (ko) | 2017-11-22 | 2020-07-29 | 그릿스톤 온콜로지, 인코포레이티드 | 신생항원에 대한 접합 에피토프 제시 감소 |
CN109865133B (zh) * | 2017-12-01 | 2021-07-09 | 上海桀蒙生物技术有限公司 | 个性化癌症疫苗的制备方法 |
CN109045290B (zh) * | 2018-11-02 | 2021-08-31 | 遵义医学院附属医院 | 基于内皮细胞特异分子-1的双靶标肿瘤疫苗及其制备方法 |
EP4038222A4 (en) | 2019-10-02 | 2023-10-18 | Arizona Board of Regents on behalf of Arizona State University | METHODS AND COMPOSITIONS FOR IDENTIFYING NEOANTIGENS FOR USE IN THE TREATMENT AND PREVENTION OF CANCER |
MX2022007122A (es) | 2019-12-11 | 2022-09-09 | Molecular Partners Ag | Dominios de repetición de anquirina diseñados con residuos de superficie alterados. |
AU2020401363A1 (en) * | 2019-12-11 | 2022-06-16 | Molecular Partners Ag | Recombinant peptide-MHC complex binding proteins and their generation and use |
CN113881707B (zh) * | 2021-10-25 | 2023-07-14 | 中国人民解放军军事科学院军事医学研究院 | 调控脐带间充质干细胞免疫抑制作用的产品、方法及用途 |
Family Cites Families (64)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4440859A (en) | 1977-05-27 | 1984-04-03 | The Regents Of The University Of California | Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms |
US4704362A (en) | 1977-11-08 | 1987-11-03 | Genentech, Inc. | Recombinant cloning vehicle microbial polypeptide expression |
ES8105035A1 (es) | 1978-12-22 | 1981-05-16 | Biogen Nv | Un metodo para producir al menos un polipeptido que muestra antigenicidad de hbv |
US4530901A (en) | 1980-01-08 | 1985-07-23 | Biogen N.V. | Recombinant DNA molecules and their use in producing human interferon-like polypeptides |
US4678751A (en) | 1981-09-25 | 1987-07-07 | Genentech, Inc. | Hybrid human leukocyte interferons |
US4766075A (en) | 1982-07-14 | 1988-08-23 | Genentech, Inc. | Human tissue plasminogen activator |
US4582800A (en) | 1982-07-12 | 1986-04-15 | Hoffmann-La Roche Inc. | Novel vectors and method for controlling interferon expression |
JPS6081130A (ja) * | 1983-10-07 | 1985-05-09 | Fujisawa Pharmaceut Co Ltd | 抗hla−a2抗体およびそれを産生するハイブリド−マ |
US4757006A (en) | 1983-10-28 | 1988-07-12 | Genetics Institute, Inc. | Human factor VIII:C gene and recombinant methods for production |
US4677063A (en) | 1985-05-02 | 1987-06-30 | Cetus Corporation | Human tumor necrosis factor |
US4810648A (en) | 1986-01-08 | 1989-03-07 | Rhone Poulenc Agrochimie | Haloarylnitrile degrading gene, its use, and cells containing the gene |
US4897445A (en) | 1986-06-27 | 1990-01-30 | The Administrators Of The Tulane Educational Fund | Method for synthesizing a peptide containing a non-peptide bond |
EP0402354A4 (en) | 1987-08-10 | 1991-03-20 | The University Of Melbourne | Molecular cloning of human rotavirus serotype 4 gene 9 encoding vp7, the major outer capsid neutralisation specific glycoprotein and expression of vp7 and fragments thereof for use in a vaccine |
US5651972A (en) | 1989-04-21 | 1997-07-29 | University Of Florida Research Foundation, Inc. | Use of recombinant swine poxvirus as a live vaccine vector |
US5119700A (en) | 1991-03-01 | 1992-06-09 | Titan Tool Company | Automatic stud driving tool having collarless retention mechanism for driven head |
US20020168374A1 (en) * | 1992-08-07 | 2002-11-14 | Ralph T. Kubo | Hla binding peptides and their uses |
AUPM322393A0 (en) | 1993-12-24 | 1994-01-27 | Austin Research Institute, The | Mucin carbohydrate compounds and their use in immunotherapy |
CA2213620A1 (en) * | 1995-04-07 | 1996-10-10 | The Regents Of The University Of California | Antibodies for the detection of hla-g |
DE69723230T2 (de) | 1996-01-17 | 2004-05-27 | Imperial College Innovations Ltd. | Immunotherapie mit verwendung von zytotoxischen t lymphozyten (ctl) |
US5849589A (en) | 1996-03-11 | 1998-12-15 | Duke University | Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells |
JP4210735B2 (ja) * | 1996-03-21 | 2009-01-21 | ファーメクサ インコーポレイテッド | Hla―a2.1結合ペプチド及びその使用 |
JP4063359B2 (ja) * | 1997-01-23 | 2008-03-19 | タカラバイオ株式会社 | 硫酸基転移酵素遺伝子 |
US6406705B1 (en) | 1997-03-10 | 2002-06-18 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
DK1015477T3 (da) * | 1997-05-30 | 2011-02-07 | Human Genome Sciences Inc | 32 humane sekreterede proteiner |
DE19739089A1 (de) | 1997-09-06 | 1999-03-11 | Hella Kg Hueck & Co | Scheinwerfer für Fahrzeuge |
CA2304208A1 (en) * | 1997-09-19 | 1999-03-25 | Dana-Farber Cancer Institute, Inc. | Intrabody-mediated control of immune reactions |
US6747137B1 (en) | 1998-02-13 | 2004-06-08 | Genome Therapeutics Corporation | Nucleic acid sequences relating to Candida albicans for diagnostics and therapeutics |
CA2375145A1 (en) | 1999-06-03 | 2000-12-14 | Cold Spring Harbor Laboratory | Substrate trapping protein tyrosine phosphatases |
WO2001022920A2 (en) * | 1999-09-29 | 2001-04-05 | Human Genome Sciences, Inc. | Colon and colon cancer associated polynucleotides and polypeptides |
WO2001059064A2 (en) * | 2000-01-31 | 2001-08-16 | Human Genome Sciences, Inc. | Nucleic acids, proteins, and antibodies |
US20020048763A1 (en) * | 2000-02-04 | 2002-04-25 | Penn Sharron Gaynor | Human genome-derived single exon nucleic acid probes useful for gene expression analysis |
WO2001072331A1 (en) * | 2000-03-31 | 2001-10-04 | Vaccine Chip Technology Aps | Immunostimulating properties of a fragment of tgf-beta |
GB0011220D0 (en) | 2000-05-10 | 2000-06-28 | Blockfoil Group Limited | Foil embossing |
US20030017167A1 (en) * | 2000-06-09 | 2003-01-23 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of colon cancer |
US20020040127A1 (en) * | 2000-06-09 | 2002-04-04 | Yuqiu Jiang | Compositions and methods for the therapy and diagnosis of colon cancer |
EP1313875A2 (en) * | 2000-07-17 | 2003-05-28 | Diadexus, Inc. | Method of diagnosing, monitoring, staging, imaging and treating colon cancer |
CA2420193A1 (en) * | 2000-08-24 | 2002-02-28 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
JP2002173450A (ja) * | 2000-12-07 | 2002-06-21 | Hokkaido Technology Licence Office Co Ltd | 糖脂質特異的硫酸転移酵素遺伝子を含む医薬組成物 |
JP2005506514A (ja) * | 2000-12-08 | 2005-03-03 | イオス バイオテクノロジー,インコーポレイティド | 結腸直腸ガンおよび/または乳ガンの診断方法、結腸直腸ガンおよび/または乳ガンのモジュレータの組成物およびスクリーニング法 |
US6455026B1 (en) | 2001-03-23 | 2002-09-24 | Agy Therapeutics, Inc. | Use of protein tyrosine phosphatase zeta as a biomolecular target in the treatment and visualization of brain tumors |
US20030118585A1 (en) | 2001-10-17 | 2003-06-26 | Agy Therapeutics | Use of protein biomolecular targets in the treatment and visualization of brain tumors |
JP2003012544A (ja) * | 2001-03-27 | 2003-01-15 | Kouji Egawa | 癌予防・治療剤 |
AU2002311787A1 (en) * | 2001-03-28 | 2002-10-15 | Zycos Inc. | Translational profiling |
CA2633171C (en) * | 2001-06-20 | 2012-11-20 | Genentech, Inc. | Antibodies against tumor-associated antigenic target (tat) polypeptides |
WO2003042661A2 (en) | 2001-11-13 | 2003-05-22 | Protein Design Labs, Inc. | Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer |
DE10225144A1 (de) * | 2002-05-29 | 2003-12-18 | Immatics Biotechnologies Gmbh | An MHC-Moleküle bindende Tumor-assoziierte Peptide |
JP2005185101A (ja) * | 2002-05-30 | 2005-07-14 | National Institute Of Agrobiological Sciences | 植物の全長cDNAおよびその利用 |
WO2003104454A1 (ja) * | 2002-06-06 | 2003-12-18 | 山之内製薬株式会社 | 新規オキシダーゼ |
US20070224201A1 (en) | 2002-10-02 | 2007-09-27 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
US20060188889A1 (en) * | 2003-11-04 | 2006-08-24 | Christopher Burgess | Use of differentially expressed nucleic acid sequences as biomarkers for cancer |
KR100494979B1 (ko) | 2003-07-14 | 2005-06-14 | 주식회사 정우인터내셔날 | 조직 절편 보호 및 해상력 증진용 액상 커버 슬립, 그제조용 조성물, 그로부터 제조된 커버슬립을 구비한슬라이드 구조체 및 그 제조방법 |
CA2536911A1 (en) * | 2003-09-01 | 2005-03-10 | Kureha Corporation | Antibody against nox1 polypeptide, method of diagnosing cancer with the use of nox1 gene and method of screening cancer growth inhibitor |
AU2005206389A1 (en) | 2004-01-27 | 2005-08-04 | Compugen Ltd. | Methods of identifying putative gene products by interspecies sequence comparison and biomolecular sequences uncovered thereby |
DE102004026135A1 (de) * | 2004-05-25 | 2006-01-05 | Immatics Biotechnologies Gmbh | An MHC-Moleküle bindende Tumor-assoziierte Peptide |
WO2006124700A2 (en) * | 2005-05-12 | 2006-11-23 | Introgen Therapeutics, Inc. | P53 vaccines for the treatment of cancers |
EP1748067A1 (en) * | 2005-07-29 | 2007-01-31 | Institut Pasteur | Polynucleotides encoding MHC class I-restricted hTERT epitopes, analogues thereof or polyepitopes |
EP1930427B1 (en) * | 2005-08-09 | 2012-04-11 | Kurume University | Squamous cell carcinoma antigen-derived peptide binding to hla-a24 molecule |
PT1806359E (pt) * | 2005-09-05 | 2010-05-25 | Immatics Biotechnologies Gmbh | Peptídeos associados a tumor ligando promiscuamente às moléculas do antigénio de leucócitos humanos (hla) da classe ii |
PL1760089T3 (pl) * | 2005-09-05 | 2010-03-31 | Immatics Biotechnologies Gmbh | Peptydy towarzyszące nowotworom, wiążące się z cząsteczkami klasy I i II antygenów ludzkich leukocytów (HLA) i związana z nimi szczepionka przeciwnowotworowa |
DK1987178T3 (en) * | 2006-02-20 | 2015-04-20 | Phylogica Ltd | Process for the construction and screening of peptide structure libraries |
EP2006377A4 (en) * | 2006-03-28 | 2009-12-09 | Dainippon Sumitomo Pharma Co | NEW TUMORANT PEPTIDES |
KR101669279B1 (ko) * | 2007-03-05 | 2016-10-26 | 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 | 암 항원 특이적 t 세포의 수용체 유전자 및 그것에 따라 코드되는 펩티드 및 이들의 사용 |
US20090004213A1 (en) * | 2007-03-26 | 2009-01-01 | Immatics Biotechnologies Gmbh | Combination therapy using active immunotherapy |
DE602008000891D1 (de) | 2008-04-30 | 2010-05-12 | Immatics Biotechnologies Gmbh | Neuartige Formulierungen von Tumor-assoziierten Peptiden, welche an menschliche Leukozytenantigene der Klasse I oder II für Impfungen binden |
-
2008
- 2008-07-25 NZ NZ582822A patent/NZ582822A/xx not_active IP Right Cessation
- 2008-07-25 EP EP12191628.2A patent/EP2562184B1/en active Active
- 2008-07-25 EP EP12191621.7A patent/EP2562182B1/en active Active
- 2008-07-25 ES ES12191628.2T patent/ES2555282T3/es active Active
- 2008-07-25 EP EP12191631.6A patent/EP2565204B1/en active Active
- 2008-07-25 AU AU2008281014A patent/AU2008281014B2/en not_active Ceased
- 2008-07-25 ES ES12191623.3T patent/ES2551589T3/es active Active
- 2008-07-25 EP EP15193843.8A patent/EP3042914B1/en active Active
- 2008-07-25 EP EP12191623.3A patent/EP2562183B1/en active Active
- 2008-07-25 PL PL15193843T patent/PL3042914T3/pl unknown
- 2008-07-25 UA UAA201001961A patent/UA103751C2/ru unknown
- 2008-07-25 ES ES08785106.9T patent/ES2689725T3/es active Active
- 2008-07-25 ES ES12191631.6T patent/ES2553229T3/es active Active
- 2008-07-25 HU HUE12191628A patent/HUE027057T2/en unknown
- 2008-07-25 UA UAA201001962A patent/UA101810C2/ru unknown
- 2008-07-25 CN CN200880100806.0A patent/CN101765610B/zh not_active Expired - Fee Related
- 2008-07-25 ES ES10014673.7T patent/ES2553207T3/es active Active
- 2008-07-25 KR KR1020137015148A patent/KR101313915B1/ko active IP Right Grant
- 2008-07-25 PL PL12191631T patent/PL2565204T3/pl unknown
- 2008-07-25 PL PL08785106T patent/PL2183278T3/pl unknown
- 2008-07-25 CN CN201510814551.6A patent/CN105566450A/zh active Pending
- 2008-07-25 EP EP08785106.9A patent/EP2183278B1/en active Active
- 2008-07-25 HU HUE12191631A patent/HUE025636T2/en unknown
- 2008-07-25 CA CA2694805A patent/CA2694805C/en not_active Expired - Fee Related
- 2008-07-25 JP JP2010517325A patent/JP5484326B2/ja not_active Expired - Fee Related
- 2008-07-25 EA EA201000207A patent/EA018456B1/ru not_active IP Right Cessation
- 2008-07-25 PL PL12191623T patent/PL2562183T3/pl unknown
- 2008-07-25 HU HUE12191621A patent/HUE026776T2/en unknown
- 2008-07-25 PL PL10014673T patent/PL2338907T3/pl unknown
- 2008-07-25 ES ES12191621.7T patent/ES2553270T3/es active Active
- 2008-07-25 KR KR1020107001885A patent/KR101291394B1/ko active IP Right Grant
- 2008-07-25 HU HUE12191623A patent/HUE027164T2/en unknown
- 2008-07-25 PL PL12191621T patent/PL2562182T3/pl unknown
- 2008-07-25 US US12/180,045 patent/US8080634B2/en active Active
- 2008-07-25 MX MX2010001090A patent/MX2010001090A/es active IP Right Grant
- 2008-07-25 CN CN201310724191.1A patent/CN103864893B/zh not_active Expired - Fee Related
- 2008-07-25 BR BRPI0813626-2A2A patent/BRPI0813626A2/pt not_active Application Discontinuation
- 2008-07-25 WO PCT/EP2008/006153 patent/WO2009015842A2/en active Application Filing
- 2008-07-25 KR KR1020127005723A patent/KR101351195B1/ko active IP Right Grant
- 2008-07-25 PL PL12191628T patent/PL2562184T3/pl unknown
- 2008-07-25 HU HUE10014673A patent/HUE026142T2/en unknown
- 2008-07-25 ES ES15193843.8T patent/ES2689851T3/es active Active
- 2008-07-25 EP EP10014673.7A patent/EP2338907B1/en active Active
-
2010
- 2010-10-29 US US12/915,473 patent/US8669230B2/en active Active
-
2011
- 2011-12-19 HK HK11113659.2A patent/HK1159129A1/xx not_active IP Right Cessation
-
2013
- 2013-08-26 HK HK13109940.7A patent/HK1183039A1/xx not_active IP Right Cessation
- 2013-08-26 HK HK13109945.2A patent/HK1183041A1/xx not_active IP Right Cessation
- 2013-08-26 HK HK13109939.0A patent/HK1183038A1/xx not_active IP Right Cessation
- 2013-08-26 HK HK13109944.3A patent/HK1183040A1/xx not_active IP Right Cessation
- 2013-12-23 US US14/138,421 patent/US9511128B2/en active Active
-
2014
- 2014-01-23 JP JP2014010161A patent/JP5818920B2/ja not_active Expired - Fee Related
-
2015
- 2015-09-11 JP JP2015179979A patent/JP2016040257A/ja active Pending
- 2015-11-06 US US14/934,612 patent/US9950048B2/en active Active
- 2015-11-18 JP JP2015225284A patent/JP6130469B2/ja not_active Expired - Fee Related
-
2016
- 2016-10-06 HK HK16111627.0A patent/HK1223381A1/zh unknown
- 2016-10-07 HK HK16111656.4A patent/HK1223382A1/zh not_active IP Right Cessation
-
2018
- 2018-11-20 US US16/196,402 patent/US10420800B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1223382A1 (zh) | 免疫療法的新型免疫抗原表位 | |
EP2429585A4 (en) | VACCINE IMMUNOTHERAPY | |
EP2056861A4 (en) | IMPF-IMMUNOTHERAPY | |
EP2376105A4 (en) | NKG2D-FC FOR IMMUNOTHERAPY | |
HK1159485A1 (en) | Vaccine composition containing synthetic adjuvant | |
EP2173431A4 (en) | IMMUNOSTIMULATING POLYPHOSPHAZEN COMPOUNDS FOR INTRADERMAL IMMUNIZATION | |
SI2200700T1 (sl) | Nova protitelesa | |
GB0702888D0 (en) | Novel Antibodies | |
PT2402032T (pt) | Composição imunogénica | |
GB0810869D0 (en) | Vaccine adjuvant composition | |
ZA201004304B (en) | Vaccines for malaria | |
EP2068904A4 (en) | METHODS FOR PREPARING DIAZONAMIDES | |
EP2227249A4 (en) | IMPROVED IMMUNIZING COMPOSITION | |
PL2234635T3 (pl) | Immunoterapia oparta na białkach rhoc | |
GB0805356D0 (en) | Vaccine adjuvant composition | |
GB0913680D0 (en) | Immunogenic composition | |
EP2155759A4 (en) | METHODS FOR THE PREPARATION OF DIORGANOZINC COMPOUNDS | |
GB2455650B (en) | Vaccines for brucellosis | |
EP2221062A4 (en) | NEW ADJUVANT | |
ZA201004414B (en) | Vaccines for malaria | |
GB0908885D0 (en) | Mycobacterial antigens | |
GB0714158D0 (en) | Immunogenic composition | |
GB0723044D0 (en) | Lyophillised antigen composition | |
GB0723900D0 (en) | Lyophillised antigen composition | |
IL206011A0 (en) | New adjuvant |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20210727 |